フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular...
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial -Phase 2 OK-101 efficacy...
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event LONDON and NEW YORK, March...
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain OK-101 is the first IND clearance granted by...
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain OK-101 is the first IND clearance granted by FDA for a drug to...
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2...
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 LONDON and NEW YORK, Jan. 05, 2024 (GLOBE...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit...
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction Pricing of a registered direct offering for $1.64M of 1,092,600...
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”) OKYO plans...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED"...
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約